Inclusion Criteria:

- Histologic or cytologic confirmation of advanced NSCLC (stage IIIB with
supraclavicular lymph node metastases or pleural effusion or stage IV) on entry into
study

- One or more measurable lesions at least 10 mm in the longest diameter (LD) by spiral
CT scan or 20 mm with conventional techniques according to RECIST criteria

- Chemotherapy-naïve (prior chemotherapy in the adjuvant setting completed more than 3
months before the trial entry is accepted).

- Female or male aged 70 years or above

Exclusion Criteria:

- Patients must not have received prior anti-cancer therapy except in the adjuvant
setting

- Inadequate end-organ function or Evidence of severe or uncontrolled systemic disease
or any concurrent condition which in the Investigator's opinion makes it undesirable
for the patient to participate in the trial

- Significant cardiovascular event (e.g. myocardial infarction, superior vena cava
[SVC] syndrome, New York Heart Association [NYHA] classification of heart disease ³2)
within 3 months before entry, or presence of cardiac disease that in the opinion of

- History of arrhythmia or QTc with Bazett's correction unmeasurable or ≥ 480 msec on
screening ECG